Knights of Columbus Asset Advisors LLC Reduces Stock Position in Insulet Corporation $PODD

Knights of Columbus Asset Advisors LLC decreased its stake in shares of Insulet Corporation (NASDAQ:PODD) by 73.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,568 shares of the medical instruments supplier’s stock after selling 12,669 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Insulet were worth $1,410,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in PODD. TD Waterhouse Canada Inc. raised its holdings in shares of Insulet by 2,014.3% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 444 shares of the medical instruments supplier’s stock worth $136,000 after acquiring an additional 423 shares during the period. AustralianSuper Pty Ltd grew its holdings in shares of Insulet by 54.8% in the third quarter. AustralianSuper Pty Ltd now owns 317,658 shares of the medical instruments supplier’s stock valued at $98,071,000 after purchasing an additional 112,490 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Insulet by 8.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,255 shares of the medical instruments supplier’s stock worth $4,710,000 after purchasing an additional 1,126 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Insulet by 1.2% during the third quarter. Bank of New York Mellon Corp now owns 409,055 shares of the medical instruments supplier’s stock worth $126,287,000 after purchasing an additional 4,898 shares during the period. Finally, Pier 88 Investment Partners LLC boosted its holdings in Insulet by 145.7% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 6,610 shares of the medical instruments supplier’s stock valued at $2,041,000 after purchasing an additional 3,920 shares during the last quarter.

Insulet Trading Up 0.3%

Shares of PODD stock opened at $255.81 on Friday. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The company has a 50 day moving average price of $291.55 and a 200 day moving average price of $309.12. The stock has a market capitalization of $18.00 billion, a P/E ratio of 74.15, a price-to-earnings-growth ratio of 1.42 and a beta of 1.40. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The firm’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.08 EPS. Equities research analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Truist Financial cut their price target on shares of Insulet from $412.00 to $390.00 and set a “buy” rating for the company in a report on Thursday, December 18th. TD Cowen cut Insulet from a “buy” rating to a “hold” rating and set a $294.00 target price for the company. in a research note on Monday, January 26th. Sanford C. Bernstein reduced their target price on Insulet from $410.00 to $380.00 and set an “outperform” rating on the stock in a research report on Friday, January 9th. Raymond James Financial increased their price target on Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a research report on Thursday, January 22nd. Twenty equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $375.05.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.